Get the Stockscreener App
10.24
0.89%
0.09
Pre-market:
10.04
-0.20
-1.95%
Keros Therapeutics Inc stock is traded at $10.24, with a volume of 347.43K.
It is up +0.89% in the last 24 hours and down -2.48% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$10.15
Open:
$10.35
24h Volume:
347.43K
Relative Volume:
0.93
Market Cap:
$202.67M
Revenue:
$244.06M
Net Income/Loss:
$87.01M
P/E Ratio:
5.6224
EPS:
1.8213
Net Cash Flow:
$105.95M
1W Performance:
+2.40%
1M Performance:
-2.48%
6M Performance:
-51.77%
1Y Performance:
-24.48%
1-Day Range:
$9.98
$10.41
1-Week Range:
$9.69
$10.47
52-Week Range:
$9.69
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
10.24 | 202.67M | 244.06M | 87.01M | 105.95M | 1.8213 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-24 | Reiterated | Oppenheimer | Outperform |
| Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
Keros Therapeutics director Charles W. Newton sells $5,521 in shares - Investing.com
Insider Sell: Charles Newton Sells Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics Hits 52-Week Low at $9.69 Amidst Major Decline - Markets Mojo
Keros Therapeutics (KROS) director Newton sells 550 shares in planned trade - Stock Titan
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 99% Upside - TradingView
KROS Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline AdvancesNon-GAAP Earnings - newsline.com
[144] Keros Therapeutics, Inc. SEC Filing - Stock Titan
Keros Therapeutics director Nima sells $28,166 in company stock By Investing.com - Investing.com Nigeria
KROS: KER-065 targets muscle regeneration in DMD, with strong early data and a solid financial runway - TradingView
Keros Therapeutics director Nima sells $28,166 in company stock - Investing.com
Director at Keros Therapeutics (NASDAQ: KROS) logs 2,625-share sale - Stock Titan
Director at Keros Therapeutics (KROS) sells 2,625 shares in Rule 10b5-1 trade - Stock Titan
Keros Therapeutics (KROS) Faces Selling Pressure as Shares Approach Key SupportATR Trailing Stop - newsline.com
How (KROS) Movements Inform Risk Allocation Models - Stock Traders Daily
Insider Sell: Alpna Seth Sells Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics director granted RSUs and options | KROS Insider Trading - Stock Titan
Keros Therapeutics (KROS) director sells 2,625 shares under Rule 10b5-1 plan - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director receives RSU and stock option awards - Stock Titan
Keros Therapeutics (KROS) grants RSUs and stock options to director - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director receives RSUs and options grant - Stock Titan
Keros Therapeutics (KROS) director awarded RSUs and stock options - Stock Titan
Keros Therapeutics Stockholders Approve Directors and Governance Matters - TipRanks
Keros Therapeutics (NASDAQ: KROS) backs directors, auditor and pay - Stock Titan
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $21.83, Implies 107% Upside - TradingView
Keros Therapeutics CEO to Present at Goldman Sachs Conference - The Globe and Mail
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Keros Therapeutics CEO to speak at Goldman Sachs health conference - Stock Titan
Keros Therapeutics (Nasdaq: KROS) CEO to join Goldman Sachs healthcare fireside chat - Stock Titan
KROS Q1 2026 Earnings: EPS Miss of $1.21 as Pre-Revenue Biotech Continues Clinical InvestmentTech Earnings Analysis - newsline.com
Keros Therapeutics (KROS) Edges Lower Near Key Support ZoneDescending Triangle - The Legal Advocate
Keros Therapeutics (KROS) Edges Higher Amid Consolidation Near Key ResistanceResistance Breakout Stocks - The Legal Advocate
Trading Systems Reacting to (KROS) Volatility - Stock Traders Daily
Keros Therapeutics (KROS) Edges Higher as Biotech Sector Shows Mixed SignalsVolume Breakout Ideas - newsline.com
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
KROS Turns to Next Wave of TGF-Beta Muscle Therapies - The Globe and Mail
Should You Buy KROS After Q1 Miss and Takeda Deal Reset? - The Globe and Mail
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026 - The Globe and Mail
Keros Therapeutics (KROS) Q1 2026 Disappoints — EPS $-1.21 Below $-1.04 ViewsQuarterly Earnings Report - Newser
Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates - MSN
Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles - Streetwise Reports
Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans - Streetwise Reports
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16 - Moomoo
Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan - Stock Titan
Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN
Keros Therapeutics, Inc.common stock (NQ: KROS - The Chronicle-Journal
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20 - Yahoo Finance
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $20 to $20 - Moomoo
Nantahala's 1.36M-share stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year - The Globe and Mail
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):